In a randomized controlled trial of patients with uncontrolled moderate-to-severe asthma on inhaled corticosteroids, Brodalumab, a human monoclonal antibody that blocks the activity of IL-17A, IL-17B and IL-25 through binding to IL-17RA, failed to show a change in ACQ score, asthma symptoms or lung function in the whole population; however, the authors reported a trend towards improvement in ACQ score in a small subgroup of patients with high bronchodilator reversibility [103]. Here, IL17RA is linked to asthma.